# A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-first-in-human-study-of-a166-in-patients-with-locally-advanced-metastatic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yongheng Liu,Wei Lian,Xi Zhao,Wei‐Xiang Qi,Jian Xu,Xiao Liang,Qing Yan,Tongtong Xue,Jingyi Wang |
| Citations | 50 |
| DOI | 10.1200/jco.2020.38.15_suppl.1049 |
| Fields | Chemistry,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3028620337 |
| Type | conference-abstract |
| Year | 2020 |

## Paper authors

- [Jingyi Wang](https://scholariq.org/researchers/jingyi-wang/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Paper topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Click Chemistry and Applications](https://scholariq.org/topics/click-chemistry-and-applications/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.